|
186 Products |
| 186 Products |
|
1696 Diseases |  |
94663 News |  |
| «12...10301031103210331034103510361037103810391040...10631064» |
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed, Combination therapy: A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 24, 2013
P2, N=20, Active, not recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial completion: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies (clinicaltrials.gov) - Nov 24, 2013
P2, N=54, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Hydrogel Patch for the Treatment of Eczema (clinicaltrials.gov) - Nov 21, 2013
P=N/A, N=23, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=30 --> 23
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML (clinicaltrials.gov) - Nov 21, 2013
P3, N=150, Terminated, Sponsor: Stanford University
N=30 --> 23 Recruiting --> Terminated; Poor accrual
- Enrollment change: Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) (clinicaltrials.gov) - Nov 21, 2013
P2, N=75, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Terminated; Poor accrual N=36 --> 75
- ||||| mapracorat (BOL-303242-X) / Bayer
Enrollment change, Surgery: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (clinicaltrials.gov) - Nov 21, 2013
P3, N=363, Completed, Sponsor: Bausch & Lomb Incorporated
N=36 --> 75 N=300 --> 363
- | Istodax (romidepsin) / Astellas, BMS
Clinical: Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma (clinicaltrials.gov) - Nov 21, 2013
P1/2, N=48, Recruiting, Sponsor: Weill Medical College of Cornell University
N=300 --> 363 Not yet recruiting --> Recruiting
- ||| mapracorat (BOL-303242-X) / Bayer
Trial completion: Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days (clinicaltrials.gov) - Nov 21, 2013
P1, N=61, Completed, Sponsor: Bausch & Lomb Incorporated
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| mapracorat (BOL-303242-X) / Bayer
Trial completion, Surgery: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (clinicaltrials.gov) - Nov 21, 2013
P3, N=363, Completed, Sponsor: Bausch & Lomb Incorporated
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| mapracorat (BOL-303242-X) / Bayer
Enrollment change, Surgery: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (clinicaltrials.gov) - Nov 20, 2013
P3, N=369, Completed, Sponsor: Bausch & Lomb Incorporated
Recruiting --> Completed N=300 --> 369
- | Clinical: Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma (clinicaltrials.gov) - Nov 20, 2013
P1/2, N=45, Active, not recruiting, Sponsor: Mayo Clinic
N=300 --> 369 Recruiting --> Active, not recruiting
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure (clinicaltrials.gov) - Nov 20, 2013
P2, N=50, Active, not recruiting, Sponsor: Austrian Forum Against Cancer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| mapracorat (BOL-303242-X) / Bayer
Trial completion, Surgery: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (clinicaltrials.gov) - Nov 20, 2013
P3, N=369, Completed, Sponsor: Bausch & Lomb Incorporated
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
Trial completion: BBD: Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 20, 2013
P2, N=79, Completed, Sponsor: Austrian Forum Against Cancer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dexamethasone / Generic mfg., melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial completion: LEOMEX: A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis (clinicaltrials.gov) - Nov 20, 2013
P2, N=50, Completed, Sponsor: University of Heidelberg
Active, not recruiting --> Completed Recruiting --> Completed
- Korlym (mifepristone) / Corcept Therap
New P4 trial: Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism (clinicaltrials.gov) - Nov 19, 2013
P4, N=20, Recruiting, Sponsor: Mount Sinai School of Medicine
- atorvastatin / Generic mfg.
Trial withdrawal: Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial (clinicaltrials.gov) - Nov 19, 2013
P2/3, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed Not yet recruiting --> Withdrawn
- atorvastatin / Generic mfg.
Enrollment change: Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial (clinicaltrials.gov) - Nov 19, 2013
P2/3, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Withdrawn N=100 --> 0
- | dexamethasone injection / Generic mfg.
New P4 trial: Effect of Intravenous Lidocaine and Dexamethasone Combination on Postoperative Sore Throat, Cough and Hoarseness. (clinicaltrials.gov) - Nov 19, 2013
P4, N=168, Recruiting, Sponsor: B.P. Koirala Institute of Health Sciences
- New P4 trial: Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 19, 2013
P4, N=20, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- ||||| filanesib (ARRY-520) / Pfizer
Metastases: A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma (clinicaltrials.gov) - Nov 19, 2013
P2, N=75, Recruiting, Sponsor: Array BioPharma
- methylprednisolone oral / Generic mfg.
Clinical: Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse (clinicaltrials.gov) - Nov 17, 2013
P4, N=48, Recruiting, Sponsor: Germans Trias i Pujol Hospital
- |||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Trial completion: Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects (clinicaltrials.gov) - Nov 17, 2013
P2, N=72, Completed, Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
N=100 --> 0 Active, not recruiting --> Completed
- |||| fluticasone propionate inhalation powder / Generic mfg.
Trial completion: A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids (clinicaltrials.gov) - Nov 17, 2013
P2, N=622, Completed, Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Triesence (triamcinolone acetonide injectable suspension) / Novartis, Ilaris (canakinumab) / Novartis
Trial completion: β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) (clinicaltrials.gov) - Nov 17, 2013
P3, N=200, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- dexamethasone / Generic mfg.
Trial termination: Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate (clinicaltrials.gov) - Nov 17, 2013
P1, N=15, Terminated, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Completed Completed --> Terminated; Replaced by another study
- dexamethasone / Generic mfg.
Enrollment change: Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate (clinicaltrials.gov) - Nov 17, 2013
P1, N=15, Terminated, Sponsor: Rutgers, The State University of New Jersey
Completed --> Terminated; Replaced by another study N=24 --> 15
- Xalkori (crizotinib) / Pfizer, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open, Combination therapy: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Nov 17, 2013
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 15 Not yet recruiting --> Recruiting
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment open: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (clinicaltrials.gov) - Nov 17, 2013
P1/2, N=144, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- |||| Armonair Respiclick (fluticasone propionate MDPI) / Teva
Trial completion: A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications (clinicaltrials.gov) - Nov 17, 2013
P2, N=622, Completed, Sponsor: Teva Pharmaceutical Industries
Suspended --> Recruiting Active, not recruiting --> Completed
- | hydrocortisone / Generic mfg.
Trial initiation date: HyStOON: Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock. (clinicaltrials.gov) - Nov 16, 2013
P2/3, N=60, Recruiting, Sponsor: Centre Hospitalier Régional d'Orléans
Active, not recruiting --> Completed Initiation date: Apr 2013 --> Nov 2013
- | hydrocortisone / Generic mfg.
Enrollment open: HyStOON: Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock. (clinicaltrials.gov) - Nov 16, 2013
P2/3, N=60, Recruiting, Sponsor: Centre Hospitalier Régional d'Orléans
Initiation date: Apr 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- || methylprednisolone acetate / Generic mfg.
New P2/3 trial: Effectiveness of Steroid Injection in Treating Patients With Lateral Epicondylitis (clinicaltrials.gov) - Nov 14, 2013
P2/3, N=78, Completed, Sponsor: Isfahan University of Medical Sciences
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 14, 2013
P2, N=164, Recruiting, Sponsor: Pharmacyclics
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | betamethasone / Generic mfg.
Enrollment open: Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial (clinicaltrials.gov) - Nov 14, 2013
P3, N=2800, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Recruiting Suspended --> Recruiting
- ||||| Vesanoid (tretinoin) / Roche
New P1/2 trial: Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 13, 2013
P1/2, N=70, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||||| Budenofalk (budesonide gastro-resistant) / Dr Falk
Trial completion: SCCMS: SOIBD Collagenous Colitis Maintenance Study (clinicaltrials.gov) - Nov 13, 2013
P3, N=92, Completed, Sponsor: Dr. Falk Pharma GmbH
Suspended --> Recruiting Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
New P1/2 trial: Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma (clinicaltrials.gov) - Nov 12, 2013
P1/2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Trial completion: Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) - Nov 12, 2013
P1, N=23, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Nov 11, 2013
P1/2, N=5, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=32 --> 5
- carfilzomib / Generic mfg.
Clinical: SWOG-S1304: S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma (clinicaltrials.gov) - Nov 10, 2013
P2, N=140, Recruiting, Sponsor: Southwest Oncology Group
N=32 --> 5 Not yet recruiting --> Recruiting
- hydrocortisone / Generic mfg.
Clinical: MENHIR: Methylprednisolone N Acetylcysteine in Hepatic Resections (clinicaltrials.gov) - Nov 8, 2013
P2, N=50, Terminated, Sponsor: Istituto Clinico Humanitas
Not yet recruiting --> Recruiting Recruiting --> Terminated; The first phase was completed
- hydrocortisone / Generic mfg.
Clinical: MENHIR: Methylprednisolone N Acetylcysteine in Hepatic Resections (clinicaltrials.gov) - Nov 8, 2013
P2, N=50, Terminated, Sponsor: Istituto Clinico Humanitas
Recruiting --> Terminated; The first phase was completed N=150 --> 50
- Ultibro (glycopyrronium/indacaterol) / Novartis
Trial withdrawal: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (clinicaltrials.gov) - Nov 7, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=150 --> 50 Suspended --> Withdrawn
- Ultibro (glycopyrronium/indacaterol) / Novartis
Trial withdrawal: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (clinicaltrials.gov) - Nov 7, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Suspended --> Withdrawn Suspended --> Withdrawn
- Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment change: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (clinicaltrials.gov) - Nov 7, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Suspended --> Withdrawn N=554 --> 0
- Ultibro (glycopyrronium/indacaterol) / Novartis
Enrollment change: A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD (clinicaltrials.gov) - Nov 7, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=554 --> 0 N=554 --> 0
- ||||| Nasonex (mometasone furoate nasal spray) / Merck (MSD)
Enrollment closed, Surgery: Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps (clinicaltrials.gov) - Nov 7, 2013
P3, N=100, Active, not recruiting, Sponsor: Intersect ENT
N=554 --> 0 Recruiting --> Active, not recruiting
- Decadron (dexamethasone) / Merck (MSD)
Enrollment change: Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting (clinicaltrials.gov) - Nov 7, 2013
P4, N=122, Completed, Sponsor: Sergio Bergese
Recruiting --> Active, not recruiting N=200 --> 122
- ||| New P1 trial: Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers (clinicaltrials.gov) - Nov 7, 2013
P1, N=84, Completed, Sponsor: Pearl Therapeutics, Inc.